Researchers have reported encouraging results from preclinical studies of SOL-257, an experimental gene therapy designed to address underlying disease mechanisms in ALS. In two mouse models of ALS, the therapy improved motor function and extended survival, suggesting it may help slow disease progression rather than just manage symptoms. These findings support the potential of gene-based approaches to offer more durable, targeted treatment options for people living with ALS. While further research is needed, the results add momentum to the growing pipeline of innovative therapies aimed at changing the course of this devastating disease. Read more (via ALS News Today).